The invention related to thiazolo-naphthyl acids BACKGROUND The present invention relates generally to thiazolo-naphthyl acids and methods of using them. The serine protease inhibitor PAI-1 is one of the primary inhibitors of the fibrinolytic system. The fibrinolytic system includes the proenzyme plasminogen, which is converted to the active enzyme, plasmin, by one of two tissue type plasminogen activators, ;-PA or w-PA. PAI-1 is the principal physiological inhibitor of/-PA and «-PA. One of plasmin's main functions in the fibrinolytic system is to digest fibrin at the site of vascular injury. The fibrinolytic system, however, is not only responsible for the removal of fibrin from circulation but is also involved in several other biological processes including ovulation, embryogenesis, intima proliferation, angiogenesis, tumorigenesis, and atherosclerosis. Elevated levels of PAI-l have been associated with a variety of diseases and conditions including those associated with impairment of the fibrinolytic system. For example, elevated levels of PAI-1 have been implicated in thrombotic diseases, e.g., diseases characterized by formation of a thrombus that obstructs vascular blood flow locally or detaches and embolizes to occlude blood flow downstream. (Krishnamurti, Blood, 69, 798 (1987); Reilly, Arteriosclerosis and Thrombosis, 11, 1276 (1991); Carmeliet, Journal of Clinical-Investigation, 92, 2756 (1993), Rocha, Fibrinolysis, 8, 294, 1994; Aznar, Haemostasis 24, 243 (1994)). f Antibody neutralization of PAI-1 activity resulted in promotion of endogenous thrombolysis and reperfusion (Biemond, Circulation, 91, 1175 (1995); Levi, Circulation 85, 305, (1992)). Elevated levels of PAI-1 have also been implicated i-n diseases such as polycystic ovary syndrome (Nordt, Journal of clinical Endocrinology and Metabolism, 85, 4, 1563 (2000)). bone loss induced by estrogen deficiency (Daci, Journal of Bone and Mineral Research, 15, 8, 1510 (2000)), cystic fibrosis, diabetes, chronic periodontitis, lymphomas, diseases associated with extracellular matrix accumulation, malignancies and diseases associated with neoangiogenesis, associated with infections, and diseases associated with increased uPA levels such as breast and ovarian cancer. In view of the foregoing, there exists a need for inhibitors of PAI-1 activity and methods of using them to modulate PAI-1 expression or activity, for example, in treating disorders associated with elevated PAI-1 levels. SUMMARY In one aspect, the present invention relates to thiazolo-naphthyl acids of the following formula: (Figure Removed) Formula 1 or a solvate, hydrate or pharmaceutical ly acceptable salt or ester form thereof; wherein: Ar is aryl or heteroaryl; R, is hydrogen, Ci-C)2 alkyl, Ce-n aryl, C6-i4ar(C|^)alkyl, -(CH2)p-heteroaryl, -(CH2)p-CO-aryl, -(CH2)p-CO-heteroaryl, -(CH2)p-CO-(C,-C6)alkyl, C2-C7 alkenyl, C2-C7 alkynyl, Cs-Cg cycloalkyl, halogen, d-Cj perfluoroalkyl, or C|-C3perfluoroalkoxy; R2 and R3 are independently hydrogen, C|-C!2 alkyl, C6.\4aryl, C6-i4ar(Ci.6)aIkyI, -(CH2)p-heteroaryl, halogen, CrC3 perfluoroalkyl, C]-C3perfluoroalkoxy, Cj-Ca alkoxy, alkoxyaryl, nitro, carboxy(C|-C6 alkyl), carbamide, carbamate, or C3-C8 cycloalkyl; R, is -CH(R6)(CH2)nR5, -C(CH3)2R^, -CH(R5)(CH2)nR<;, -CH(R5)C6H4R6) -CH(R5)C6H3(C02H)2 CH(R5)C6H2(CO2H)3, or an acid mimic; R5 is hydrogen, Ci-Ce alkyl, Q-C|2 aryl, aralkyl, C3-Cs cycloalkyl, or -(CH2)n(R7); R6 is COH, tetrazole, or PO3H; is S , or N n is from 0 to 6; p is from 0 to 3; b is from 0 to 6; and a is from 0 to 6. The present invention further provides, inter alia, methods of using thiazolonaphthyl acids to, for example, modulate PAI-1 expression and/or activity. In certain methods, a therapeutically effective amount of one or more compounds of the .present invention is administered (o a subject to treat a PAI-1 related disorder. Exemplary methods are those that involve inhibiting PAI-1 activity in the subject, such as that associated with impairment of the fibrinolytic system. In certain embodiments, one or more compounds of the present invention is administered to a subject to treat thrombosis, e.g., venous thrombosis, arterial thrombosis, cerebral thrombosis, and deep vein thrombosis, atrial fibrillation, pulmonary fibrosis, thromboembolic complications of surgery, cardiovascular disease, e.g., myocardial ischemia, atherosclerotic plaque formation, chronic obstructive pulmonary disease, renal fibrosis, polycystic ovary syndrome, Alzheimer's disease, or cancer. DETAILED DESCRIPTION A. GENERAL OVERVIEW The present invention provides compounds that inhibit PAI-1 activity, processes for preparing such compounds, pharmaceutical compositions containing such compounds, and methods for using such compounds, for example, in medical therapies. Preferred compounds have properties that are useful for the prevention and/or inhibition, of a wide variety of diseases and disorders including those involving the production and/or action of PAI-1. These include disorders resulting from impairment of the fibrinolytic system including, but not limited to, thrombosis, coronary heart disease, renal fibrosis, atherosclerotic plaque formation, pulmonary disease, myocardial ischemia, atrial fibrillation, coagulation syndromes, thromboembolic s oFs«rgery;'poSer-aTerial occlusion and pulmonary fibrosis. Other disorders include, but are not limited to, polycystic ovary syndrome, Alzheimer's disease, and cancer. The terms "alkyl" and "alkylene," as used herein, whether used alone or as part of another group, refer to substituted or unsubstttuted aliphatic hydrocarbon chains, the difference being that alkyl groups are monovalent (i.e., terminal) in nature whereas alkylene groups are divalent and typically serve as linkers. Both include, but are not limited to, straight and branched chains containing from 1 to about 12 carbon atoms, preferably 1 to about 6 carbon atoms, unless explicitly specified otherwise. For example, methyl, ethyl, propyl, isopropyl, butyl, /-butyl and tbutyl are encompassed by the term "alkyl." Specifically included within the definition of "alkyl" are those aliphatic hydrocarbon chains that are optionally substituted. Accordingly, the alkyl groups described herein refer to both unsubstituted or substituted groups. Representative optional substituents include, but are not limited to, halogens, -CN, hydroxy, oxo (=O), acyloxy, alkoxy, amino, amino substituted by one or two alkyl groups of from 1 to 6 carbon atoms, aminoacyl, acylamino, thioalkoxy of from 1 to 6 carbon atoms, substituted thioalkoxy of from 1 to 6 carbon atoms, and trihalomethyl. Preferred substituents include halogens, -CN, -OH, oxo (=Q), and amino groups. The carbon number as used in the definitions herein refers to carbon backbone and carbon branching, but does not include carbon atoms of the substituents, such as alkoxy substitutions and the like. The term "alkenyl", as used herein, whether used alone or as part of another group, refers to a substituted or unsubstituted aliphatic hydrocarbon chain and includes, but is not limited to, straight and branched chains having 2 to about 10 carbon atoms (unless explicitly specified otherwise) and containing at least one double bond. Preferably, the alkenyl moiety has 1 or 2 double bonds. Preferably, the alkenyl moiety has about 2 to about 7 carbon atoms. Such alkenyl moieties can exist in the E or Z conformations and the compounds of this invention include both conformations. Specifically included within the definition of "alkenyl" are those aliphatic hydrocarbon chains that are optionally substituted. Accordingly, the alkenyl groups described herein refer to both unsubstituted or substituted groups. Representative optional substituents include, but are not limited to, halogens, -CN, hydroxy, acyloxy, alkoxy, amino, amino substituted by one or two alkyl groups of from 1 to 6 carbon atoms, aminoacyl, acylamino, thioalkoxy of from 1 to 6 carbon atoms, substituted thioaikoxy of from 1 to 6 carbon atoms, and trihalomethyl. Heteroatoms, such as O or S attached to an alkenyl should not be attached to a carbon atom that is bonded to a double bond. Preferred substituents include halogens, -CN, -OH, and ammo groups. herein, whether used alone or as part of another group, refers to a substituted or unsubstituted aliphatic hydrocarbon chain and includes, but is not limited to, straight and branched chains having 2 to about 10 carbon atoms (unless explicitly specified otherwise) and containing at least one triple bond. Preferably, the alkynyl moiety has about 2 to about 7 carbon atoms. In certain embodiments, the alkynyl can contain more than one triple bond and, in such cases, the alkynyl group must contain at least four carbon atoms. Specifically included within the definition of "alkynyl" are those aliphatic hydrocarbon chains that are optionally substituted. Accordingly, the alkynyl groups described herein refer to both unsubstituted or substituted groups. Representative optional substituents include, but are not limited to, halogens, -CN, hydroxy, acyloxy, alkoxy, amino, ammo substituted by one or two alkyl groups of from 1 to 6 carbon atoms, aminoacyl, acylamino, thioalkoxy of from 1 to carbon atoms, substituted thioalkoxy of from 1 to 6 carbon atoms, and trihalomethyl. Preferred substituents include halogens, -CN, -OH, and amino groups. Heteroatoms, such as O or S attached to an alkynyl should not be attached to the carbon that is bonded to a triple bond. The term "cycloalkyl" as used herein, whether alone or as part of another group, refers to a substituted or unsubstituted alicyclic hydrocarbon group having 3 to about 20 carbon atoms (unless explicitly specified otherwise), preferably 3 to about 8 carbon atoms, more preferably 3 to about 6 carbon atoms. Specifically included within the definition of "cycloalkyl" are those alicyclic hydrocarbon groups that are optionally substituted. Accordingly, the cycloalkyl groups described herein refer to both unsubstituted or substituted groups. Representative optional substituents include, but are not limited to, halogens, -CN, hydroxy, oxo (=O), acyloxy, alkoxy, amino, amino substituted by one or two alkyl groups of from 1 to 6 carbon atoms, aminoacyl, acylamino, thioalkoxy of from 1 to 6 carbon atoms, substituted thioalkoxy of from 1 to 6 carbon atoms, and trihalomethyl. The term "aryl", as used herein, whether used alone or as part of another group, is defined as a substituted or unsubstituted aromatic hydrocarbon ring group having 5 to about 50 carbon atoms (unless explicitly specified otherwise) with from about 6 to about 14 carbon atoms being preferred, more preferably from about 6 to about 12 carbon atoms. The "aryl" group can have a single ring or multiple condensed rings. The term "aryl" includes, but is not limited to phenyl, a-naphthyl, p-naphthyl, biphenyl, anthryl, tetrahydronaphthyl, fluorenyl, indanyl, biphenylen'yl, and acenaphthenyl. Specifically included within the definition of "aryl" are those aromatic groups thai are optionally substituted. Accordingly, the aryl groups (e.g., phenyl, naphthyl, and fluorenyl) described herein refer to both unsubstituted or substituted groups. In representative embodiments of the present invention, the "aryl" groups are optionally substituted withSMm-l tb^subsiliiuefitS^yo^SJil-'ifdm'the group consisting of acyloxy, hydroxy, acyl, alky] of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, C3-C6c.ycloaIkyI, -(CH2)P-C3-C6 cycloalkyl, halogen, Ci-Ca perfluoroalkyl, d-C3 perfluoroalkoxy, -(CH2)p-phenyl, -O(CH2)p-phenyI, amino, aniino substituted by one or two alkyl groups of from 1 to 6 carbon atoms, aminoacyl, acylamino, azido, cyano, halo, nitro, thioalkoxy of from 1 to 6 carbon atoms, substituted thioalkoxy of from 1 to 6 carbon atoms, and trihalomethyl. For example, the "aryl" groups can be optionally substituted with from 1 to 3 groups selected from C(-C6 alkyl, C|-C6 alkoxy, hydroxy, C3-C6 cycloalkyl, -(CH2)P-C3-C6 cycloalkyl, halogen, CrC3 perfluoroalkyl, Ci-C3 perfluoroalkoxy, -(CH2)p-phenyl, and -O(CH2)p-phenyl. In these embodiments, the phenyl group of-(CH2)p-phenyI and -O(CH2)Pphenyl can be optionally substituted with, for example, from 1 to 3 groups selected from Ci-Cs alkyl, Ci-C6 alkoxy, -(CH^Vphenyl phenyl, halogen, trifluoromethyl or trifluoromethoxy. P is an integer from 0 to 3. Preferred aryl groups include phenyl and naphthyl. Preferred substituents on the aryl groups herein include Ct-C(, alkyl, Ci-C6 alkoxy, halo, cyano, nitro, trihalomethyl, and Ci-Ce thioalkoxy. As used herein, the term "heteroaryl", whether used alone or as part of another group, is defined as a substituted or unsubstituted aromatic heterocyclic ring system. Heteroaryl groups can have, for example, from about 3 to about 50 carbon atoms (unless explicitly specified otherwise), with from about 4 to about 10 being preferred. In some embodiments, heteroaryl groups are aromatic heterocyclic ring systems having about 4 to about 14 ring atoms and containing carbon atoms and 1,2,3 or 4 oxygen, nitrogen or sulfur heteroatoms. Representative heteroaryl groups are furan, thiophene, indole, azaindole, oxazole, thiazole, isoxazole, isothiazole, imidazole, N-methylimidazole, pyridine, pyrimidine, pyrazine, pyrrole, N-methylpyrrole, pyrazole, N-methylpyrazole, 1,3,4-oxadiazole, 1,2,4-triazole, 1-methyl-1,2,4- triazole, IH-tetrazole, 1 -methyltetrazole, benzoxazole, benzothiazole, benzofuran, benzothiophene, benzisoxazole, benzimidazole, N-methylbenzimidazole, azabenzimidazole, indazole, quinazoline, quinoline, and isoquinoline. Bicyclic aromatic heteroaryl groups include phenyl, pyridine, pyrimidine or pyridizine rings that are (a) fused to a 6-membered aromatic (unsaturated) heterocyclic ring having one nitrogen atom; (b) fused to a 5- or 6-membered aromatic (unsaturated) heterocyclic ring having two nitrogen atoms; (c) fused to a 5-membered aromatic (unsaturated) heterocyclic ring having one nitrogen atom together with either one oxygen or one sulfur atom; or (d) fused to a 5-membered aromatic {unsaturated) heterocyclic ring having one heteroatom selected from O, N or S. Specifically included within the definition of "heteroaryl" are those aromatic groups that are optionally substituted. Accordingly, the l, benzothienyl, indolyl, pyrazolyl, and oxazolyl) described herein refer to both unsubstituted or substituted groups. In representative embodiments of the present invention, the "heteroaryl" groups are optionally substituted with from 1 to 5 substituents selected from the group consisting of acyloxy, hydroxy, acyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, substituted alkyl, substituted alkoxy, substituted alkenyl, substituted alkynyl, Cj- Ce cycloalkyl, -(CH2)P-C3-C6 cycloalkyl, Ci-Ca perfluoroalkyl, Ci-C3 perfluoroalkoxy, -(CH2)Pphenyl, -O(CH2)p-phenyl, amino, amino substituted by one or two alkyl groups of from 1 to 6 carbon atoms, aminoacyl, acylamino, azido, cyano, halo, nitro, thioalkoxy of from 1 to 6 carbon atoms, substituted thioalkoxy of from 1 to 6 carbon atoms, and trihalomethyl. In some embodiments of the present invention, the "heteroaryl" groups can be optionally substituted with from 1 to 3 groups selected from Ci-C6 alkyl, C,-C6 alkoxy, hydroxy, C3-C6 cycloalkyl, -(CH2)PCa- Ce cycloalkyl, halogen, Ci-Ca perfluoroalkyl, Ci-C3 perfluoroalkoxy, -(CH2)p-phenyl, and - O(CH2)p-phenyl. In these embodiments, the phenyl group of -(CH2)p-phenyl and -O(CH2)Pphenyl can be optionally substituted with from 1 to 3 groups selected from Q-Ce alkyl, Q-Ce alkoxy, phenyl, halogen, trifluoromethyl or trifluoromethoxy. P is an integer of from 0 to 3. Preferred heteroaryls of the present invention include substituted and unsubstituted furanyl, thienyl, benzofuranyl, benzothienyl, indolyl, pyrazolyl, and oxazolyl. The term "alkoxy" as used herein, refers to the group Ra-O- wherein Ra is an alkyl group as defined above. The term "thioalkoxy" as used herein, refers to the group -O-Ra-S wherein Ra is an alkyl group as defined above. Specifically included within the definition of "alkoxy" and "thioalkoxy" are those groups that are optionally substituted. Preferred substituents on alkoxy and thioalkoxy groups include halogens, -CN, -OH, and amino groups. The term "alkoxyaryl" as used herein, refers to the group Ra-O-aryl- wherein Ra is an alkyl group as defined above and aryl is as defined above. The term "arylalkyl" or "aralkyl" refers to the group -R3-Rt>, where Ra is an alkylene group as defined above, substituted by Rb, an aryl group,. Preferred aralkyl groups include C6.nar(C|.6)alkyl groups. Aralkyl groups of the present invention are optionally substituted. For example, in preferred embodiments, the benzyl groups of the present invention are optionally substituted with from 1 to 3 groups selected from C\-C(, alkyl, Ci-Ce alkoxy, hydroxy, C3-C6cycloalkyl, -(CH2)P-C3-C6cycloalkyl, halogen, CrC3 perfluoroalkyl, d-Ca perfluoroalkoxy, -(CH2)p-phenyl, and -O(CH2)p-phenyl. Examples of arylalkyl moieties include, but are not limited to, benzyl, 1-phenylethyl, 2-phenylethyl, 3-phenylpropyl, 2-phenyIpropyl and the like. The term "perfluoroalkyl", as used herein, whether used alone or as part of another group, refers to a saturated aliphatic hydrocarbon having 1 to 6 carbon atoms and two or v more fluorine atoms and includes, but is not limited to, straight or branched chains, such as -CF3, -CH2CF3, -CF2CF3 and -CH(CF3)2- The term "halogen" or "halo" refers to chlorine, bromine, fluorine, and iodine. The term "carbamide," as used herein, refers to the group -C(O)NR'R" where R' and R" are independently hydrogen, alkyl, aryl or cycloalkyJ as defined herein. The term "carbamate," as used herein, refers to the group -OC(O)NR'R" where R1 and R" are independently hydrogen, alkyl, aryl or cycloalkyl as defined herein. The term "acyl" refers to a radical of the formula RC(O)-, where R is hydrogen, alkyl, aryl, or cycloalkyl as defined herein. Suitable acyl radicals include formyl, acetyl, propionyl, and the like. The term "acyloxy" refers to radicals of the formula RC(O)O-, where R is hydrogen, alky], aryl or cycloalkyl as defined herein. Suitable acyloxy radicals include CH3COO-, CH3CH2COO-, benzoyloxy, and the like. The term "acylamino" refers to radicals of the formula RC(O)NH- where R is hydrogen, alkyl, aryl, or cycloalkyl as defined herein. The term "aminoacyl" refers to radicals of the formula -(R)o-3C(O)NH2 where R is alkylene as previously described. The term "treating" or "treatment" refers to any indicia of success in amelioration of an injury, pathology, or condition, including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the injury, pathology, or condition more tolerable to the patient; slowing in the rate of degeneration or decline; making the final point of degeneration less debilitating; or improving a subject's physical or mental well-being. The treatment or amelioration of symptoms can be based on objective or subjective parameters; including the results of a physical examination, neurological examination, and/or psychiatric evaluation. "Treating" or "treatment of a PAI-1 related disorder" includes preventing the onset of symptoms in a subject that may be predisposed to a PAI-1 related disorder but does not yet experience or exhibit symptoms of the disorder (prophylactic treatment), inhibiting the symptoms of the disorder (slowing or arresting its development), providing relief from the symptoms or side-effects of the disorder (including palliative treatment), and/or relieving the symptoms of the disorder (causing regression). Accordingly, the term "treating" includes the administration of the compounds or agents of the present invention to a subject to prevent or delay, to alleviate, or to arrest ot inhibit development of the symptoms or conditions associated with PAI-l related disorders. A skilled medical practitioner will know how to use standard methods to determine whether a patient is suffering from a disease associated with enhanced levels and/or activity of PAI-1, e.g., by examining the patient and determining whether the patient is suffering from a disease known to be associated with elevated PAI-1 levels or activity or by assaying for PAI-1 levels in blood plasma or tissue of the individual suspected of suffering from a PAI-1 related disease and comparing PAI-1 levels in the blood plasma or tissue of the individual suspected of suffering from a PAI-1 related disease to PAI-1 levels in the blood plasma or tissue of a healthy individual. Methods known in the art for the detection of nucleic acids and proteins can be used for determining PAI-1 levels in a subject, e.g., PCR, northern and Southern blots, dot blots, nucleic acid arrays, western blots, immunoassays such as immunoprecipitation, ELISA, proteomics assays, and the like. Increased PAI-1 levels are indicative of disease. In healthy individuals, PAI-1 is found at low levels in the plasma (for example, from about 5-26 ng/mL), but it is elevated significantly in a number of diseases, including, for example, atherosclerosis (Schneiderman J. et. a/, Proc NadAcad Sci 89: 6998-7002, 1992) deep vein thrombosis (Juhan-Vague I, et. al, Thromb Haemost 57: 67-72, 1987), and non-insulin dependent diabetes mellitus (Juhan-Vague I, et. al, Thromb Haemost 78: 565-660, 1997). PAI-1 stabilizes both arterial and venous thrombi, contributing respectively to coronary arterial occlusion in post-myocardial infarction (Hamsten A, et. al. Lancet 2:3-9, 1987), and venous thrombosis following post-operative recovery from orthopedic surgery. (Siemens HJ, et. (Figure Removed) Clin Anesthesia 11: 622-629,1999). Plasma PAI-I is also elevated, for example, in postmenopausal women, and has been proposed to contribute to the increased incidence of cardiovascular disease in this population (Koh K et. al, NEnglJMed 336: 683-690, 1997). The term "PAI-1 related disorder or disease" refers to any disease or condition that is associated with increased or enhanced expression or activity of PAI-1 or increased or enhanced expression or activity of a gene encoding PAI-1. Examples of such increased activity or expression include the following: activity of the protein or expression of the gene encoding the protein is increased above the level of that in normal subjects; activity of the protein or expression of the gene encoding the protein is in an organ, tissue or cell where it is not normally detected in normal subjects (i.e. spatial distribution of the protein or expression of the gene encoding the protein is altered); activity of the protein or expression of the gene encoding the protein is increased when activity of the protein or expression of the gene encoding the protein is present in an organ, tissue or cell for a longer period than in a normal subjects (i.e.. duration of activity of the protein or expression of the gene encoding the protein is increased). A normal subject is a subject not suffering from a PAI-1 related disorder or disease. In some embodiments of the present invention, the PAI-I related disorder is not associated with hyperglycemia. A PAI- 1 related disorder that is not associated with hyperglycemia is one, for example, that is not caused by elevated levels of glucose in the blood. The term "pharmaceutically acceptable excipient " means an excipient that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic, and desirable, and includes excipients that are acceptable for veterinary use as well as for human pharmaceutical use. Such excipients can be solid, liquid, semisolid, or, in the case of an aerosol compositi 0115 gaseo u s. "Pharmaceutically acceptable salts and esters" refers to salts and esters that are pharmaceutically acceptable and have the desired pharmacological properties. Such salts include, for example, salts that can be formed where acidic protons present in the compounds are capable of reacting with inorganic or organic bases. Suitable inorganic salts include, for example, those formed with the alkali metals or alkaline earth metals, e.g. sodium and potassium, magnesium, calcium, and aluminum. Suitable organic salts include, for example, those formed with organic bases such as the amine bases, e.g. ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like. Pharmaceutically acceptable salts can also include acid addition salts formed from the reaction of amine moieties in the parent compound with inorganic acids (e.g. hydrochloric and hydrobromic acids) and organic acids (e.g. acetic acid, citric acid, maleic acid, and the alkane- and arene-sulfonic acids such as methanesulfonic acid and benzenesulfonic acid). Pharmaceutically acceptable esters include esters formed from carboxy, sulfonyloxy, and phosphonoxy groups present in the compounds, e.g. CI-G alkyl esters. When there are two acidic groups present, a pharmaceutically acceptable salt or ester can be a mono-acid-mono-salt or ester or a di-salt or ester; and similarly where there are more than two acidic groups present, some or all of such groups can be saiified or esterified. Compounds named in this invention can be present in unsalified or unesterified form, or in saiified and/or esterified form, and the naming of such compounds is intended to include both the original (unsalified and unesterified) compound and its pharmaceutically acceptable salts and esters. Also, certain compounds named in this invention can be present in more than one stereoisomeric form, and the naming of such compounds is intended to include all single stereoisomers and all mixtures (whether racemic or otherwise) of such stereoisomers. The terms "inhibitors," "activators," and "modulators" as used in connection with expression or activity refer to inhibitory, activating, or modulating molecules, respectively. Inhibitors of the present invention are compositions that, inhibit expression of PAI-1 or bind to, partially or totally block stimulation, decrease, prevent, delay activation, inactivate, desensitize, or down regulate the activity of PAI-1. Samples or assays comprising PAI-1 can be treated with a composition of the present invention and compared to control samples without a composition of the present invention. Control samples (untreated with compositions of the present invention) can be assigned a relative activity value of 100%. In certain embodiments, inhibition of PAI-1 is achieved when the activity value relative to the control is about 80% or less, optionally 50% or 25, 10%, 5% or 1%. The terms "pharmaceutically acceptable", "physiologically tolerable" and grammatical variations thereof, as they refer to compositions, carriers, diluents and reagents, are used interchangeably and represent that the materials are capable of administration to or upon a human without the production of undesirable physiological effects such as nausea, dizziness, gastric upset and the like which would be to a degree that would prohibit administration of the compound. A "therapeutically effective amount" or "pharmaceutically effective amount" means an amount that, when administered to a subject for treating a disease, is sufficient to effect treatment for that disease. Except when noted, the terms "subject" or "patient" are used interchangeably and refer to mammals such as human patients and non-human primates, as well as experimental animals such as rabbits, rats, and mice, and other animals. Accordingly, the term "subject" or "patient" as used herein means any mammalian patient or subject to which the compounds of the invention can be administered. In an exemplary embodiment of the present invention, to identify subject patients for treatment according to the methods of the invention, accepted screening methods are employed to determine risk factors associated with a targeted or suspected disease or condition or to determine the status of an existing disease or condition in a subject. These screening methods include, for example, conventional work-ups to determine risk factors that may be associated with the targeted or suspected disease or condition. These and other routine methods allow the clinician to select patients in need of therapy using the methods and formulations of the present invention. In some embodiments of the present invention, the subject to be treated with the methods of the present invention does not have hyperglycemia and/or a disease that has been caused by hyperglycemia. Methods of determining whether a subject has hyperglycemia are known in the art and include, for example, performing a glucose test that measures the level of glucose in the blood. Two exemplary tests that can be used to measure the presence of excess levels of glucose in the blood include a test that measures the amount of glucose in ihe blood after an overnight fast and a test that measures the body's ability to process (Figure Removed) excess sugar presented atter drinking "a high glucose test. Typically a subject having a fa sugar level (sugar level after an overnight fast) of about 64 to about 110 mg/dl does not have hyperglycemia whereas as person having a fasting sugar level of greater than 1 1 0 mg/dl has elevated blood sugar levels. A value above about 140 mg/dl on at least two occasions typically signifies that the subject has diabetes. [0036] When any variable occurs more than one time in any constituent or in any formula, its definition in each occurrence is independent of its definition at every other occurrence. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. B. THIAZOLO-NAPHTHYL ACIDS [0037] As noted above, the compounds of the present invention include those of the following formula: Formula 1 or solvates, hydrates or pharmaceutically acceptable salts or ester forms thereof; wherein: Ai is aryl or heteroaryl; RI is hydrogen, C|-C|2 alkyl, Cs-uaryl, C)p-phenyl. hydrogen, Ci-C6 alkyl, phenyl-(CH2)p-, halogen or Ci-C3 perfluoroalkyl. R4 is -CHRsCOzH, -CH2-tetrazole or an acid mimic. RS is hydrogen or optionally substituted benzyl. Ar is phenyl, naphthyl, furanyl, thienyl, benzofuranyl, benzothienyl, indolyl, pyrazolyl, oxazolyl or fluorenyl or alternatively, Ar is phenyl, furanyl, thienyl, pyrazolyl, oxazolyl, or fluorenyl, or a solvate, hydrate or pharmaceutically acceptable salt or ester form thereof. Exemplary compounds of Formulas 1 to 6 include those in which the definitions have one or more, e.g. all, of the following values: RI is hydrogen or halogen; Ra and R3 are independently hydrogen or halogen; R4 is -CHR5CO2H or -CH2-tetrazole; RS is hydrogen or optionally substituted benzyl; and Ar is unsubstituted phenyl or phenyl substituted with 1 to 3 groups selected from CrC6 alkyl, CrC« alkoxy, hydroxy, C3-C6cycloalkyl, -(CH2)P-C3-C6cycloalkyl, halogen, C|-C3 perfluoroalkyl, Ci-Cs perfluoroalkoxy, -(CH2)p-phenyl, and -O(CH2)p-phenyl. In certain embodiments when b is from 1 to 6, Ar is phenyl, furanyl, thienyl, pyrazolyl, oxazolyl, or fluorenyl and when b is 0, Ar is furanyl, benzofuranyl, benzothienyl, indolyl, pyrazolyl, oxazolyl or fluorenyl. Compounds of the present invention also include prodrugs and stereoisomers formulas 1-6. In some embodiments of the present invention, RI is hydrogen, halogen, Ci-Ci2 alkyl, Ci-C3 perfluoroalkyl, or -(CH2)p-phenyI wherein the phenyl ring is optionally substituted with Ci-Cg alkyl, Ci-Cg alkoxy, halogen, trifluoromethyl, or trifluoromethoxy. In certain embodiments of the present invention, R\ is hydrogen or halogen. For example, in some embodiments, RI is hydrogen or bromine. In some compounds of the present invention, R2 and R3 are, independently, hydrogen, Ci-Ci2 alkyl, halogen, CrC3 perfluoroalkyl, or -(CH2)p-phenyl wherein the phenyl ring is optionally substituted with C\-C(, alkyl, Ci-Ce alkoxy, halogen, trifluoromethyl, or trifluoromethoxy . In certain embodiments of the present invention, R2 is hydrogen and R3 is hydrogen or halogen. For example R3 is hydrogen or bromine. In some compounds, R4 is -CHR5CO2H, -CH2-tetrazole, -CH(R5)C6H4CO:H) CH(Rs)C6H3(CC)2H)2 or an acid mimic. In certain embodiments, R^ is unsubstituted CH-COOH, subsftMted erl2G©0H^ <^NetirSzoie or -CH(R5)C6H4CO2H. In some embodiments, for example R, is unsubstituted CH2COOH; CH2COOH wherein the methylene group is substituted with benzyl; -CH2-tetrazole; or -CH(R5)C6H4CO2H. In some compounds of the present invention, the phenyl or benzyl groups of R5 are optionally substituted with from 1 to 3 groups selected from Ci-Ce alkyl, C\-C(, alkoxy, hydroxy, C3-C6cycloalkyl, -(CHzJp-Cs-Cecycloalkyl, halogen, Ci-Ca perfluoroalkyl, C\-C$ perfluoroalkoxy, -(CH2)p-phenyl, and -O(CH2)p-phenyl. In some compounds, Ar is substituted or unsubstituted phenyl, naphthyl, furanyl, thienyl, benzofbranyl, benzothienyl, indolyl, pyrazolyl, oxazolyl or fluorenyl. In certain embodiments, Ar is a substituted or unsubstituted phenyl. In some compounds of the present invention, the substituent OR^j is in the 6 position relative to the thiazole ring (the numbering system used is shown in Formula 3). Exemplary thiazolo-naphthyl acids of the present invention include, but are not limited to, 3-phenyl-2-{[6-(2-phenyl-l,3-thiazol-4-yl)-2-naphthyl]oxy}propanoic acid or a pharmaceutically acceptable salt or ester form thereof; 5-({[6-(2-phenyl- l,3-thiazol-4-yl)-2- naphthyl]oxy}methyl)-l//-tetraazole or a pharmaceutically acceptable salt or ester form thereof; 2-{[l-bromo-6-(2-phenyl-l,3-thiazol-4-yl)-2-naphthyI]oxy}-3-phenylpropanoic acid or a pharmaceutically acceptable salt or ester form thereof; {[l-bromo-6-(2-phenyl-l,3-thiazol-4-yl)- 2-naphthyl]oxy} acetic acid or a pharmaceutically acceptable salt or ester form thereof; 5-({[lbromo- 6-(2-phenyl-1,3-thiazol-4-yl)-2-naphthyl]oxy}methyl)-l/f-tetraazole or a pharmaceutically acceptable salt or ester form thereof; ({6-[2-(2,6-dichlorobenzyl)-l,3-thiazol-4- yl]-2-naphthyl}oxy)acetic acid or a pharmaceutically acceptable salt or ester form thereof; 2-{[l - bromo-6-(5-bromo-2-phenyl-l,3-thiazol-4-yl)-2-naphthyl]oxy}-3-phenylpropanoic acid or a pharmaceutically acceptable salt or ester form thereof; and 4-({[l-bromo-6-(2-phenyl-l,3- thiazol-4-yl)-2-naphthyl]oxy}methyl)benzoic acid or a pharmaceutically acceptable salt or ester form thereof. The present invention also provides compositions comprising the thiazolonaphthyl acids of the present invention, including those compounds of formulas 1-6 or a stereoisomer or pharmaceutically acceptable solvate, hydrate, salt or ester fonn thereof, and one or more pharmaceutically acceptable carriers, excipients, or diluents. Such compositions include pharmaceutical compositions for treating or controlling disease states.or conditions associated with increased PAI-1 activity. In certain embodiments, the compositions comprise mixtures of one or more thiazolo-naphthyl acids. of formulas 1-6 contain stcreogcnic carbon atoms or other chiral elements and thus give rise to stereoisomers, including enantiomers and diastereomers. The present invention includes all of the stereoisomers of fonnulas 1-6, as well as mixtures of the stereoisomers. Throughout this application, the name of the product, where the absolute configuration of an asymmetric center is not indicated, is intended to embrace the individual stereoisomers as well as mixtures of stereoisomers. Where an enantiomer is preferred, it can, in some embodiments, be provided substantially free of the corresponding enantiomer. Thus, an enantiomer substantially free of the corresponding enantiomer refers to a compound that is isolated or separated via separation techniques or prepared free of the corresponding enantiomer. "Substantially free," as used herein, means that the compound is made up of a significantly greater proportion of one enantiomer. In preferred embodiments, the compound is made up of at least about 90% by weight of a preferred enantiomer. In other embodiments of the invention, the compound is made up of at least about 99% by weight of a preferred enantiomer. Preferred enantiomers can be isolated from racemic mixtures by any method known to those skilled in the art, including high performance liquid chromatography (HPLC) and the formation and crystallization of chiral salts, or preferred enantiomers can be prepared by methods described herein. Methods for the preparation of preferred enantiomers are described, for example, in Jacques, et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen, S.H., et al., Tetrahedron 33:2725 (1977); Eliel, E.L. Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); and Wilen, S.H. Tables of Resolving Agents and Optical Resolutions p. 268 (E.L. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN 1972). Exemplary salt forms of the compounds herein include, but are not limited to, sodium salts and potassium salts. Other exemplary salt forms of these compounds include, but are not limited to, those formed with pharmaceutically acceptable inorganic and organic bases or acids known in the art. The acids include, for example, acetic, propionic, lactic, citric, tartaric, succinic, fumaric, maleic, malonic, mandelic, malic, phthalic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, napthalenesulfonic, benzenesulfonic, toluenesulfonic, camphorsulfonic, and similarly known acceptable aids when a compound of this invention contains a basic moiety. Salt forms prepared using inorganic bases include hydroxides, carbonates or bicarbonates of the therapeutically acceptable alkali metals or alkaline earth metals, such as sodium potassium, magnesium, calcium and the like. Acceptable organic bases include amines, such as benzylamine, mono-, di- and trialkylarnines, preferably ihose having alkyl groups of from 1 to 6 carbon atoms, more preferably 1 to 3 carbon atoms, such as ,, melhyl&Mhe; diWeftylaiillM'/thfi'iethytamine, ethylamine, diethylamine, triethylamine, mono-, di-, and triethanolamine. Exemplary salts also include alkylene diamines containing up to 6 £earbon atoms, such as hexamethylenediamine; cyclic saturated or unsaturated bases containing up to 6 carbon atoms, including pyrrolidine, piperidine, morpholine, piperazine and their N-alkyl and N-hydroxyalkyl derivatives, such as N-methyl-morpholine and N-(2-hydroxyethyl)- piperidine, or pyridine. Quaternary salts can also be formed, such as tetralkyl forms, such as tetramethyl forms, alkyl-alkanol forms, such as methyl-triethanol or trimethyl-monoethanol forms, and cyclic ammonium salt forms, such as N-methylpyridinium, N-methyl-N-(2- hydroxyethyl)-morpholinium, N,N-di-methylmorpholinium, N-methyl-N-(2-hydroxyethyl)- morpholinium, or N,N-dimethyl-piperidinium salt forms. These salt forms can be prepared using the acidic compound(s) of Formulas 1-6 and procedures known in -e art. Exemplary ester forms of the compounds of this invention include, but are not limited to, straight chain alkyl esters having from 1 to 6 carbon atoms or branched chain alkyl groups containing 1 to 6 carbon atoms, including methyl, ethyl, propyl, butyl, 2-methylpropyl and 1,1-dimethylethyl esters, cycloalkyl esters, alkylaryl esters, benzyl esters, and the like. Other exemplary esters include, but are not limited to, those of the formula -COORI3 wherein is selected from the formula: (Figure Removed) wherein R, RIS, Rie, and R]7 are independently selected from hydrogen, alkyl of from 1 to 10 carbon atoms, aryl of 6 to 12 carbon atoms, arylalkyl of from 6 to 12 carbon atoms; heteroaryl or alkylheteroaryl wherein the heteroaryl ring is bound by an alkyl chain of from 1 to 6 carbon atoms. Acids and acid mimics, according to the in tntion, are defined as proton or hydrogen donating groups. Exemplary acid mimics or mimetics of the present invention include pharmaceuticaily useful carboxylic acids and acid mimics or mimetics known in the art, such as those described in R. Silverman, The Organic Chemistry of Drug Design and Drug Action, Academic Press (1992) and others. Exemplary acid mimics or mimetics include, but are not limited to, tetrazole, tetronic acid or groups having the formula: (Table Removed) wherein R,g is Ci-C6 alkyl, C2-C6 alkenyl, C3-C6 cycloalkyl, -CH2-(C3-C6 cycloalkyl), C3-C6 cycloalkenyl, -CH2-(C3-C6 cycloalkenyl), optionally substituted aryl or heteroaryl groups or optionally substituted -aryI(Ci-C6)alkyl or-heteroaryl(Ci-G6)alkyl, with the ar>'l and heteroaryl groups as defined herein. Preferred compounds of the present invention inhibit PAI-1 activity. Accordingly, the compounds can be used for the treatment, including prevention, inhibition, and/or amelioration of PAI-1 related disorders in a subject, including, for example, in the treatment of noninsulin dependent diabetes mellitus, in the treatment of cardiovascular disease, and in the treatment of thrombotic events associated with coronary artery and cerebrovascular disease. Using the methods of the present invention, a skilled medical practitioner will know how to administer the compounds of the present invention, including those represented by formulas 1-6, to a subject suffering from any of the diseases associated with increased PAI-1 activity or expression, e.g., diabetes or cardiovascular disease, in order to effect treatment for that disease. in •6neiie¥empfa'i^y;igiT\ooiiliment) the compounds of the present invention are administered to a subject in order to treat disease processes involving thrombotic and prolhrombotic states which include, but are not limited to, formation of atherosclerotic plaques venous and arterial thrombosis, myocardial ischemia, atrial fibrillation, deep vein thrombosis, coagulation syndromes, pulmonary thrombosis, cerebral thrombosis, thromboembolic complications of surgery (such as joint or hip replacement), and peripheral arterial occlusion. Any disease or condition that is associated with increased PAI-1 activity or expression in a subject can be treated using the compounds of the present invention. Exemplary diseases and conditions include stroke, e.g., stroke associated with or resultirig from atrial fibrillation; diseases associated with extracellular matrix accumulation including, but not limited to, renal fibrosis, chronic obstructive pulmonary disease, polycystic ovary syndrome, restenosis, renovascular disease, and organ transplant rejection; diseases associated with neoangiogenesis, including, but not limited to, diabetic retinopathy; Alzheimer's disease, e.g., by increasing or normalizing levels of plasmin concentration in a subject; myelofibrosis with myeloid metaplasia, e.g., by regulating stromal cell hyperplasia and increases in extracellular matrix proteins. The compounds of the present invention can be used to treat, for example, diabetic nephropathy and renal dialysis associated with nephropathy; malignancies or cancers, including, but not limited to, leukemia, breast cancer and ovarian cancer; rumors, including, but not limited to, liposarcomas and epithelial tumors; septicemia; obesity; insulin resistance; proliferative diseases, including, but not limited to, psoriasis; conditions associated with abnormal coagulation homeostasis; low grade vascular inflammation; cerebrovascular diseases; hypertension; dementia; osteoporosis; arthritis; asthma; heart failure; arrhythmia; angina, including, but not limited to, angina pectoris; atherosclerosis and sequelae; kidney failure; multiple sclerosis; osteoporosis; osteopenia; dementia; peripheral vascular disease; peripheral arterial disease; acute vascular syndromes; microvascular diseases including, but not limited to, nephropathy, neuropathy, retinopathy and nephrotic syndrome; hypertension; Type I and II diabetes and related diseases; hyperglycemia; hyperinsulinemia; malignant lesions; premalignant lesions; gastrointestinal malignancies; coronary heart disease, including, but not limited to, primary and secondary prevention of myocardial infarction, stable and unstable angina, primary prevention of coronary events, and secondary prevention of cardiovascular events; and inflammatory diseases, including, but not limited to, septic shock and the vascular damage associated with infections. The compounds of the present invention can also be administered to a subject in combination with a second therapeutic agent, including, but not limited to, prothrombolytic, .a'n'di:a'iHf0b'agu'lai«'^gi£)nt:§,'dr in conjunction with other therapies, for example, protease inhibitor-containing highly active antiretroviral therapy (HAART) for the treatment of diseases which originate from fibrinolytic impairment and hyper-coagulability of HIV- 1 infected patients. In certain embodiments, the compounds of the present invention can be administered in conjunction with and/or following processes or procedures involving maintaining blood vessel patency, including, but not limited to, vascular surgery, vascular graft and stent patency, organ, tissue and cell implantation and transplantation. The compounds of the present invention can also be used for the treatment of blood and Wood products used in dialysis, blood storage in the fluid phase, especially ex vivo platelet aggregation. The compounds of the present invention can also be administered to a subject as a hormone replacement agent or to reduce inflammatory markers or C-reactive protein. The compounds can be administered to improve coagulation homeostasis, to improve endothelial function, or as a topical application for wound healing, e.g., the prevention of scarring. The compounds of the present invention can be administered to a subject in order to reduce the risk of undergoing a myocardial revascularization procedure. The present compounds can also be added to human plasma during the analysis of blood chemistry in hospital settings to determine the fibrinolytic capacity thereof. In certain embodiments, the compounds of the present invention can be used as imaging agents for the identification of metastatic cancers. C SYNTHESIS OVERVIEW Compounds of the present invention can be prepared by those skilled in the art of organic synthesis employing conventional methods that utilize readily available reagents and starting materials. Representative compounds of the present invention can be prepared using the following synthetic schemes. The skilled practitioner will know how to make use of variants of these process steps, which in themselves are well known in the art. In the following reaction schemes, the substituents are selected from the groups defined above. Scheme 1 (Table Removed) D. PHARMACEUTICAL COMPOSITIONS The present invention provides thiazolo-naphthyl acids as Pharmaceuticals. In a preferred embodiment, the compounds of the present invention are formulated as Pharmaceuticals to treat diseases, for example, those associated with increased PAI-1 activity, e.g.. by inhibiting PAI-1 activity in a subject. In general, the compounds of the present invention can be administered as pharmaceutical compositions by any method known in the art for administering therapeutic drugs including oral, buccal, topical, systemic (e.g., transdermal, intranasal, or by suppository), or parenteral (e.g., intramuscular, subcutaneous, or intravenous injection). Compositions can take the form of tablets, pills, capsules, semisolids, powders, sustained release formulations, solutions, suspensions, emulsions, syrups, elixirs, aerosols, or any other appropriate compositions; and comprise at least one compound of this invention in combination with at least one pharmaceutically acceptable excipient. Suitable excipients are well known to persons of ordinary skill in the art, and they, and the methods of formulating the compositions, can be found in such standard references as Alfonso AR: Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton PA, 1985. Suitable liquid carriers, especially for injeclable solutions, include water, aqueous saline solution, aqueous dextrose solution, and glycols. In some embodiments of the present invention, thiazolo-naphthyl acids suitable for use in the practice of this invention will be administered either singly or in combination with at least one (Figure Removed) othef cGjTipounrfdffhis-inVeiilt'idrii^T-liJfeolo-naphthyl acids suitable for use in the practice of the present invention can also be administered with at least one other conventional therapeutic a°ent for the disease being treated. Aqueous suspensions of the invention can contain thiazolo-naphthyl acids in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients can include, for example, a suspending agent, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia, and dispersing or wetting agents such as a naturally occurring phosphatide (e.g., lecithin), a condensation product of an alkylene oxide with a fatty acid (e.g., polyoxyethylene stearate), a condensation product of ethylene oxide with a long chain aliphatic alcohol (e.g., heptadecaethylene oxycetanol), a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol (e.g., polyoxyethylene sorbitol mono-oleate), or a condensation product of ethylene oxide with a partial ester derived from fatty acid and a hexitol anhydride (e.g., polyoxyethylene sorbitan mono-oleate). The aqueous suspension can also contain one or more preservatives such as ethyl or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose, aspartame or saccharin. Formulations can be adjusted for osmolarity. Oil suspensions can be formulated by suspending a thiazolo-naphthyl acid in a vegetable oil, such as arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin; or a mixture of these. The oil suspensions can contain a thickening agent, such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents can be added to provide a palatable oral preparation, such as glycerol, sorbitol or sucrose. These formulations can be preserved by the addition of an antioxidant such as ascorbic acid. As an example of an injectable oil vehicle, see Minto, J. Pharmacol. Exp. Ther. 281:93-102, 1997. The pharmaceutical formulations of the invention can also be in the form of oil-in-water emulsions. The oily phase can be a vegetable oil or a mineral oil, described above, or a mixture of these. Suitable emulsifying agents include naturally-occurring gums, such as gum acacia and gum tragacanth, naturally occurring phosphatides, such as soybean lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan mono-oleate, and condensation products of these partial esters with ethylene oxide, such as polyoxyethylene sorbitan mono-oleate. The emulsion can also contain sweetening agents and flavoring agents, as in the formulation of syrups and elixirs. Such formulations can also contain a demulcent, a preservative, or a coloring agent. , alone or in combination with other suitable components, can be made into aerosol formulations (i.e., they can be "nebulized") to be administered via inhalation. Aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like. Formulations suitable for parenteral administration, such as, for example, by intraarticular (in the joints), intravenous, intramuscular, intradermal, intraperitoneal, and subcutaneous routes, include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. Among the acceptable vehicles and solvents that can be employed are water and Ringer's solution, an isotonic sodium chloride. In addition, sterile fixed oils can conventionally be employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid can likewise be used in the preparation of injectables. These solutions are sterile and generally free of undesirable matter. Where the compounds are sufficiently soluble they can be dissolved directly in normal saline with or without the use of suitable organic solvents, such as propylene glycol or polyethylene glycol. Dispersions of the finely divided compounds can be made-up in aqueous starch or sodium carboxymethyl cellulose solution, or in suitable oil, such as arachis oil. These formulations can be sterilized by conventional, well known sterilization techniques. The formulations can contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents, e.g., sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium laclate and the like. The concentration of thiazolo-naphthyl acids in these formulations can vary widely, and will be selected primarily based on fluid volumes, viscosities, body weight, and the like, in accordance with the particular mode of administration selected and the patient's needs. For IV administration, the formulation can be a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension. This suspension can be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation can also be a sterile injectable solution or suspension in a nontoxic parenterally-acceptable diluent or solvent, such as a solution of 1,3-butanediol. The formulations of commends can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials. ttjectrori'soMionvamf suspensions can be prepared from sterile powders, granules, and (ablets of the kind previously described. Compounds suitable for use in the practice of this invention can be administered orally. The amount of a compound of the present invention in the composition can vary widely depending on the type of composition, size of a unit dosage, kind of excipients, and other factors well known to those of ordinary skill in the art. In general, the final composition can comprise from, for example, 0.000001 percent by weight (% w) to 10 % w of the compound, preferably 0.00001 % w to 1 % w, with the remainder being the excipient or excipients. Pharmaceutical formulations for oral administration can be formulated usinsO pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical formulations to be formulated in unit dosage forms as tablets, pills, powder, dragees, capsules, liquids, lozenges, gels, syrups, slurries, suspensions, etc. suitable for ingestion by the patient. Formulations suitable for oral administration can consist of (a) liquid solutions, such as an effective amount of the packaged nucleic acid suspended in diluents, such as water, saline or PEG 400; (b) capsules, sachets or tablets, each containing a predetermined amount of the active ingredient, as liquids, solids, granules or gelatin; (c) suspensions in an appropriate liquid; and (d) suitable emulsions. Pharmaceutical preparations for oral use can be obtained through combination of the compounds of the present invention with a solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable additional compounds, if desired, to obtain tablets or dragee cores. Suitable solid excipients are carbohydrate or protein fillers and include, but are not limited to sugars, including lactose, sucrose, mannitol, or sorbitol; starch from com, wheat, rice, potato, or other plants; cellulose such as methyl cellulose, hydroxymethyl cellulose, hydroxypropylmethyl-cellulose or sodium carboxymethylcellulose; and gums including arabic and tragacanth; as well as proteins such as gelatin and collagen. If desired, disintegrating or solubilizing agents can be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate. Tablet forms can include one or more of lactose, sucrose, mannitol, sorbitol, calcium phosphates, corn starch, potato starch, microcrystalline cellulose, gelatin, colloidal silicon dioxide, talc, magnesium stearate, stearic acid, and other excipients, colorants, fillers, binders, diluents, buffering agents, moistening agents, preservatives, flavoring agents, dyes, disintegrating agents, and pharmaceutically compatible carriers. Lozenge forms can comprise the active ingredient in a flavor, e.g., sucrose, as well as pastilles comprising the active ingredient in an inert base, such as gelatri ;and glyeerHrer 3licYS3'e-a!wIo. Results are analyzed using a logarithmic best-fit equation.: rhe"'a5Sa5': isSlis'iti;v|.it:y f'Si'S41g/ml of human PAI-1 as determined from a standard curve ranging from 0-100 ng/ml. The compounds of the present invention inhibited Plasminogen Activator Inhibitor-1 as summarized in Table 1. Table I (Table Removed) a. The lCy was determined by the Antibody Assay as described above. Although the foregoing invention has been described in detail by way of example for purposes of clarity of understanding, it will be apparent to the artisan that certain changes and modifications are comprehended by the disclosure and can be practiced without undue experimentation within the scope of the appended claims, which are presented by way of illustration not limitation. All publications and patent documents cited above are hereby incorporated by reference in their entirety for all purposes to the same extent as if each were so individually denoted. What is. Claimed : 1. A compound of formula 1: (Figure Removed) or a solvate, hydrate or pharmaceutically acceptable salt or ester form thereof; wherein: Ar is aryl or heteroaryl; R is hydrogen, C-Cu alkyl, Cnaryl, C6-i4ar(Ci-6)alkyl, -(CH2)p-heteroaryl, -(CH2)p-CO-aryl, -(CH2)p-CO-heteroaryl, -(CH2)p-CO-(C,-C6)alkyI, C2-C7 alkenyl, C2-C7 alkynyl, C3-Cg cycloalkyl, halogen, or Ci-C3perfluoroalkoxy; R2 and R3 are independently hydrogen, C|-C|2 alky], CS-H aryl, C6.i4ar(Ci.6)alkyl, -(CH2)p-heteroaryl, halogen, Q-Q alkoxy, alkoxyaryl, nitro, carboxy(C|-C6 alkyl), carbamide, carbamate, or C3-Cg cycloalkyl; R4 is -CH(R6)(CH2)nR5, -C(CH3)2R6, -CH(R5)(CH2)nR^, -CH(R5)C6H4R6j -CH(R5)C6H3(CO2H)2, CH(R5)C6H2(C02H)3,or an acid mimic; R5 is hydrogen, d-Ce alkyl, C6-Ci2 aryl, aralkyi, C3-Cg cycloalkyl, or -(CH2)n(R7); R6 is CO2H, tetrazole, or PO3H; R7is -N O N S ,or n is from 0 to 6; p is from 0 to 3; b is from 0 to 6; and "a"is"ironr 0' tG;:6'fw;ttn:-Uie proviso that when b is from 1 to 6, Ar is phenyl, furanyl, thienyl, pyrazolyl, oxazolyl, or fluorenyl. 2. The compound of claim 1 wherein in the definition of RI, Ra and Ra said C|-C|2 alkyl is Ci-Cj perfluoroalkyl and said Ci-Ca alkoxy is Ci-Cs perfluoroalkoxy. 3 . The compound of claim 1 wherein RI is hydrogen, halogen, C\-C& alkyl or -(CH2)Pphenyl. 4. The compound of claim 1 wherein R2 and Rj are independently hydrogen, unsubstituted Ci-Ce alkyl, phenyl-(CH2)p-, halogen or Q-Cs perfluoroalkyl. 5. The compound of any one of claims 1 to 4 wherein R4 is -CHRsCChH, -CH2-tetrazole, -CH(R5)C6H4CO2H or an acid mimic. 6. The compound of any one of claims 1 to 5 wherein RS is hydrogen, unsubstituted benzyl or benzyl substituted with from 1 to 3 groups selected from C\-C& alkyl, Ci-Ca alkoxy, hydroxy, C3-C6cycloalkyl, -(Cf^VCs-Cecycloalkyl, halogen, C\-C) perfluoroalkyl, C\-C^ perfluoroalkoxy, -(CH2)p-phenyl, and -O(CH2)p-phenyl wherein p is from 0 to 3. 7 . The compound of any one of claims 1 to 6 having formula 2: or a solvate, hydrate or pharmaceutically acceptable salt or ester form thereof. 8 . The compound of any one of claims 1 to 6 having formula 3: (Figure Removed) Formula 3 or a solvate, hydrate or pharmaceutically acceptable salt or ester form thereof. 9 . The compound of any one of claims 1 to 8 wherein Ar is phenyl, naphthyl, furanyl, thienyl, benzofuranyl, benzothienyl, indolyl, pyrazolyl, oxazolyl, or fluorenyl. 10 . The compound of any one of claims 1 to 6 having formula 5: Formula 5 or a solvate, hydrate or pharmaceutically acceptable salt or ester form thereof wherein Rg, RIO, RH and R\2 are independently hydrogen, C\-C(, alkyl, Ci-Ce alkoxy, hydroxy, Cs-Ca cycloalkyl, -(CH2)P-C3-C6 cycloalkyl, halogen, -(CH2)p-phenyl, or-O(CH2)p-phenyl. 11 . The compound of any one of claims 1 to 6 having formula 6: (Figure Removed) Fomiula 6 20 . *Fhe method "of^lainl IS' wherein said determination is made after administration of said compound. 21. A method of modulating PAI-1 activity comprising identifying a subject in need of PAI-1 modulation and administering to the subject an effective amount of a compound of the formula (Figure Removed) or a solvate, hydrate or pharmaceutically acceptable salt or ester form thereof; wherein: Ar is aryl or heteroaryl; RI is hydrogen, Q-Cu alkyl, G^aryl, C6-i4ar(C|.<>)alkyl, -(CH2)p-heteroaryl, -(CH2)p-CO-aryl, -(CH2)p-CO-heteroaryl, -(CH2)P-CO-(C,-Chalky 1, C2-C7 alkenyl, C2-C7 alkynyl, C3-Cg cycloalkyl, halogen, or Ci-Csperfluoroalkoxy; R2 and RS are independently hydrogen, Ci-Ci2 alkyl, Cs-u aryl, C6-i4ar(Ci_6)alkyl, -(CH2)p-heteroaryl, halogen, CrQ alkoxy, aralkyl, alkoxyaryl, nitro, carboxy(Ci-C6 alkyl), carbamide, carbamate, or Cs-Cg cycloalkyl; R4 is -CH(R6)(CH2)nR5, -CCCHj^Rg, -CH(R5)(CH2)nR6, -CH(R5)C6H4R6, -CH(R5)C6H3(CO2H)2, CH(R5)C6H2(CO2H)3, or an acid mimic; RS is hydrogen, Ci-Ce alkyl, C&-C|2 aryl, aralkyl, Cs-Cg cycloalkyl, or -(CH2)n(R7); RG is CO2H, terrazole, or PO3H; R7 i s 'S ,or n is from 0 to 6; p is from 0 to 3; b is from 0 to 6; and a is from 0 to 6. 22. The method of claim 21 wherein in the definition of RI, Rz and R3 said Q-Cn alkyl is C|-C3 perfluoroalkyl and said d-C6 alkoxy is C|-C3 perfluoroalkoxy. 23. The method of claims 21 or 22 wherein Ar is phenyl, naphrhyl, furanyl, thienyl, benzofuranyl, benzothienyl, indolyl, pyrazolyl, oxazolyl or fluorenyl. 24 . The method of any one of claims 21 to 23 wherein Ar is unsubstituted phenyl or phenyl substituted with from 1 to 3 groups selected from Ci-C6 alkyl, Cj-Ce alkoxy, hydroxy,'Cs-Ce ! cycloalkyl, -(CH2)p-C3-C6 cycloalkyl, halogen, -(CH2)p-phenyl, or -O(CH2)p-phenyl. 25. The method of claim 24 wherein said Q-C6 alkyl is Ci-C3 perfluoroalkyl or said Ci-C6 alkoxy is Cj-€3 perfluoroalkoxy. 26. The method of claim 21 wherein Ar is phenyl, naphthyl, furanyl, thienyl, benzofuranyl, benzothienyl, indolyl, pyrazolyl, oxazolyl, or fluorenyl; R] is hydrogen, halogen, Cj-Cs alkyl or-(CH2)p-phenyl; R2 and R3 are independently hydrogen, unsubstituted CpCc alkyl, phenyl-(CH2)p-, halogen or d-C3 perfluoroalkyl; R4 is -CHR5CO2H, -CH2-tetrazole, -CH(R5)C6H4CO2H or an acid mimic; and RS is hydrogen or benzyl; or a solvate, hydrate or pharmaceutically acceptable salt or ester form thereof. 27 . A method for treating impairment of the fibrinolytic system, thrombosis, atrial fibrillation, pulmonary fibrosis, myocardial ischemia, stroke, thromboembolic complication of surgery, cardiovascular disease, atherosclerotic plaque fonnation, chronic obstructive pulmonary disease, renal fibrosis, Alzheimer's disease, cancer, diabetes, or polycystic ovary syndrome comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula l.as defined in any one of claims 1 to 16 or 21 to 26. 28. The method of any one "of claims 21 to 27 wherein tlie therapeutical ly effective amount is from about 25 mg/kg to about 200 nig/kg. 29. The method of claim 27 wherein the thrombosis is selected from the group consisting of venous thrombosis, arterial thrombosis, cerebral thrombosis, and deep vein tlirombosis. 30. The method of claim 27 wherein the cardiovascular disease is caused by non-insulin dependent diabetes mellitus in a subject. 31. A pharmaceutical composition comprising a compound of any one of claims 1 to 16 or 21 to 26, or a pharmaceutically acceptable salt or ester form thereof, and a pharmaceutically acceptable excipient or carrier. 32. The use of a compound as defined in any one of claims 1 to 16 or 21 to 26 in the manufacture of a medicament for treating impairment of the fibrinolytic system, thrombosis, atrial fibrillation, pulmonary fibrosis, thromboembolic complication of surgery, stroke, myocardlai ischemia, atherosclerotic plaque formation., cardiovascular disease, chronic obstructive pulmonary disease, polycystic ovary syndrome, diabetes, Alzheimer's disease, cancer, or renal fibrosis. 33. The use according to claim 32 wherein the thrombosis is selected from the group consisting of venous thrombosis, arterial thrombosis, cerebral thrombosis, and deep vein thrombosis. 34. The use according to claim 32 wherein the cardiovascular disease is caused by noninsulin dependent diabetes mellitus. 34. The Invention substantially such a* herein before described.